These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

66 related articles for article (PubMed ID: 6283067)

  • 1. The affinity of morphine for its pharmacologic receptor in vivo.
    Tallarida RJ; Cowan A
    J Pharmacol Exp Ther; 1982 Jul; 222(1):198-201. PubMed ID: 6283067
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Buprenorphine antagonism of mu opioids in the rhesus monkey tail-withdrawal procedure.
    Walker EA; Zernig G; Woods JH
    J Pharmacol Exp Ther; 1995 Jun; 273(3):1345-52. PubMed ID: 7791107
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Affinity of normorphine for its pharmacologic receptor in the naive and morphine-tolerant guinea-pig isolated ileum.
    Porreca F; Burks TF
    J Pharmacol Exp Ther; 1983 Jun; 225(3):688-93. PubMed ID: 6306216
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Potency differences for D-Phe-Cys-Tyr-D-Trp-Arg-Thr-Pen-Thr-NH2 as an antagonist of peptide and alkaloid micro-agonists in an antinociception assay.
    Sterious SN; Walker EA
    J Pharmacol Exp Ther; 2003 Jan; 304(1):301-9. PubMed ID: 12490605
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Estimation in vivo of the receptor constants of morphine in naive and morphine-tolerant rats.
    Porreca F; Cowan A; Raffa RB; Tallarida RJ
    Life Sci; 1982 Nov 15-22; 31(20-21):2355-8. PubMed ID: 6298527
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Buprenorphine: differential interaction with opiate receptor subtypes in vivo.
    Sadée W; Rosenbaum JS; Herz A
    J Pharmacol Exp Ther; 1982 Oct; 223(1):157-62. PubMed ID: 6288917
    [TBL] [Abstract][Full Text] [Related]  

  • 7. In vivo determination of mu opioid receptor turnover in rhesus monkeys after irreversible blockade with clocinnamox.
    Zernig G; Butelman ER; Lewis JW; Walker EA; Woods JH
    J Pharmacol Exp Ther; 1994 Apr; 269(1):57-65. PubMed ID: 8169852
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Morphine-receptor dissociation constant and the stimulus-effect relation for inhibition of gastrointestinal transit in the rat.
    Raffa RB; Porreca F; Cowan A; Tallarida RJ
    Eur J Pharmacol; 1982 Apr; 79(1-2):11-6. PubMed ID: 6282596
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The use of drug-receptor affinity measures in the differentiation of receptors.
    Tallarida RJ
    Fed Proc; 1982 May; 41(7):2323-7. PubMed ID: 6122613
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Interaction of mu-opioid receptor agonists and antagonists with the analgesic effect of buprenorphine in mice.
    Kögel B; Christoph T; Strassburger W; Friderichs E
    Eur J Pain; 2005 Oct; 9(5):599-611. PubMed ID: 16139189
    [TBL] [Abstract][Full Text] [Related]  

  • 11. In vivo apparent pA2 analysis for naltrexone antagonism of discriminative stimulus and analgesic effects of opiate agonists in rats.
    Walker EA; Makhay MM; House JD; Young AM
    J Pharmacol Exp Ther; 1994 Nov; 271(2):959-68. PubMed ID: 7965818
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clocinnamox antagonism of the antinociceptive effects of mu opioids in squirrel monkeys.
    Pitts RC; Allen RM; Walker EA; Dykstra LA
    J Pharmacol Exp Ther; 1998 Jun; 285(3):1197-206. PubMed ID: 9618423
    [TBL] [Abstract][Full Text] [Related]  

  • 13. In vivo studies on spinal opiate receptor systems mediating antinociception. II. Pharmacological profiles suggesting a differential association of mu, delta and kappa receptors with visceral chemical and cutaneous thermal stimuli in the rat.
    Schmauss C; Yaksh TL
    J Pharmacol Exp Ther; 1984 Jan; 228(1):1-12. PubMed ID: 6319664
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Reversibility of opioid receptor occupancy of buprenorphine in vivo.
    Englberger W; Kögel B; Friderichs E; Strassburger W; Germann T
    Eur J Pharmacol; 2006 Mar; 534(1-3):95-102. PubMed ID: 16490191
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Interaction of thymosin fraction 3 with opiate receptors].
    Zozulia AA; Khomiakov IuN; Bezvershenko IA
    Biull Eksp Biol Med; 1986 Mar; 101(3):298-300. PubMed ID: 3006826
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Nitrocinnamoyl and chlorocinnamoyl derivatives of dihydrocodeinone: in vivo and in vitro characterization of mu-selective agonist and antagonist activity.
    McLaughlin JP; Hill KP; Jiang Q; Sebastian A; Archer S; Bidlack JM
    J Pharmacol Exp Ther; 1999 Apr; 289(1):304-11. PubMed ID: 10087018
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Morphine-like discriminative stimulus effects of buprenorphine and demethoxybuprenorphine in rats: quantitative antagonism by naloxone.
    Shannon HE; Cone EJ; Gorodetzky CW
    J Pharmacol Exp Ther; 1984 Jun; 229(3):768-74. PubMed ID: 6547177
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Attenuation of tolerance to opioid-induced antinociception and protection against morphine-induced decrease of neurofilament proteins by idazoxan and other I2-imidazoline ligands.
    Boronat MA; Olmos G; García-Sevilla JA
    Br J Pharmacol; 1998 Sep; 125(1):175-85. PubMed ID: 9776358
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Blocking of enhanced sensitivity to behavioral effects of naloxone induced by narcotic agonists in rats.
    Jain R; Ray R
    Indian J Physiol Pharmacol; 2003 Oct; 47(4):407-14. PubMed ID: 15266952
    [TBL] [Abstract][Full Text] [Related]  

  • 20. In vivo receptor binding of the opiate partial agonist, buprenorphine, correlated with its agonistic and antagonistic actions.
    Dum JE; Herz A
    Br J Pharmacol; 1981 Nov; 74(3):627-33. PubMed ID: 6271322
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.